Identity
This entry covers kisspeptin-54; it is distinct from kisspeptin-10 and is not an interchangeable dose.
Selected study only; not a complete clinical review.
Peptide library
KP-54
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Randomization and blinded clinical assessment strengthen the two-dose comparison. The primary endpoint was oocyte yield, with a wide confidence interval. It was not a trial of general fertility treatment or superiority over every standard IVF trigger.
About this assessment
Selected full-text methods/results or correction sections assessed.
This assessment covers selected sources and sections. It is not a systematic review, formal risk-of-bias score, or clinician sign-off.
Editorial assessment · 2026-09-07
Who was studied
62 women at high risk of ovarian hyperstimulation during IVF.
What the sources found
A second supervised dose improved the prespecified oocyte-yield outcome versus one dose; this was not a general fertility regimen.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
This entry covers kisspeptin-54; it is distinct from kisspeptin-10 and is not an interchangeable dose.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- Ovarian hyperstimulation monitoring remained necessary; small numbers cannot establish absence of risk.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
A second supervised dose improved the prespecified oocyte-yield outcome versus one dose; this was not a general fertility regimen.
Selected study only; not a complete clinical review.
Adverseeffects
Ovarian hyperstimulation monitoring remained necessary; small numbers cannot establish absence of risk.
Selected study only; not a complete clinical review.
References
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. 2017.
PMID: 28854728
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.